Clinical Trial Update: Effects of Treatment With Aprepitant (Emend®) in HIV Infected Individuals [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating the antiemetic aprepitant (Emend) in HIV-infected individuals has completed, reporting preliminary safety and pharmacokinetic findings.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• EMEND (aprepitant)

Snippet

Sponsor: University of Pennsylvania | Conditions: HIV Infections | Phase 1 | Status: COMPLETED